Stephan Chalon

β ₂ -Adrenoceptor signaling is required for the development of an asthma phenotype in a murine model

Pharmacokinetics and Pharmacodynamics of Edivoxetine (LY2216684), a Norepinephrine Reuptake Inhibitor, in Pediatric Patients with Attention-Deficit/ Hyperactivity Disorder

Differential physiological effects of a low dose and high doses of venlafaxine in major depression

Depression

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

How strong is the evidence for the use of perioperative β blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

Relationships Between Authors of Clinical Practice Guidelines and the Pharmaceutical Industry

The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure

β-Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gsα mouse

Analysis of Randomized Controlled Trials on the Effect of Magnitude of Heart Rate Reduction on Clinical Outcomes in Patients With Systolic Chronic Heart Failure Receiving Beta-Blockers

Cell-type Specific Targeting of the α2c-Adrenoceptor

Prospects for Cardiovascular Research

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency

Percutaneous Repair or Surgery for Mitral Regurgitation

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

Anti–β1-adrenergic receptor antibodies and heart failure: causation, not just correlation

Dietary arginine alters time of symptom onset in Huntington’s disease transgenic mice

Nitric Oxide and Peroxynitrite in Health and Disease

Update on recent clinical trials in congestive heart failure

Clinical outcomes in heart failure: report from a community hospital-based registry

Trends in Heart Failure Incidence and Survival in a Community-Based Population

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Myocarditis

Two functionally distinct α2-adrenergic receptors regulate sympathetic neurotransmission

Pharmacology of carvedilol

Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy

Chronic Exposure to Beta-Blockers Attenuates Inflammation and Mucin Content in a Murine Asthma Model

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

Myocarditis

Airway Mucus Function and Dysfunction

Seven-transmembrane-spanning receptors and heart function

Use of a Continuous-Flow Device in Patients Awaiting Heart Transplantation

Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Health Outcomes Associated With Various Antihypertensive Therapies Used as First-Line Agents

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

α-Neurexins couple Ca2+ channels to synaptic vesicle exocytosis

Cardiac Intercellular Communication: Are Myocytes and Fibroblasts Fair-Weather Friends?

Myocarditis

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

In Vivo Ventricular Gene Delivery of a β-Adrenergic Receptor Kinase Inhibitor to the Failing Heart Reverses Cardiac Dysfunction

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

Cardioselective beta-blockers for chronic obstructive pulmonary disease

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy

2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

Myocyte Adrenoceptor Signaling Pathways

Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

Heterozygous α _2A -adrenergic receptor mice unveil unique therapeutic benefits of partial agonists

Forecasting the Future of Cardiovascular Disease in the United States

β-Adrenergic Receptor Signaling: An Acute Compensatory Adjustment—Inappropriate for the Chronic Stress of Heart Failure?

Contemporary Definitions and Classification of the Cardiomyopathies

Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial

Pathological Ventricular Remodeling

Fibrosis — A Common Pathway to Organ Injury and Failure

Intracoronary Adenovirus-Mediated Delivery and Overexpression of the β ₂ -Adrenergic Receptor in the Heart

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

Anti–β1-adrenergic receptor antibodies and heart failure: causation, not just correlation

HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches

Risk of Heart Failure and Death After Prolonged Smoking Cessation

Gadolinium Cardiovascular Magnetic Resonance Predicts Reversible Myocardial Dysfunction and Remodeling in Patients With Heart Failure Undergoing β-Blocker Therapy

Health outcomes associated with various antihypertensive therapies used as first-line agents

Functional disorders of the sympathetic nervous system in mice lacking the α _1B subunit (Ca _v 2.2) of N-type calcium channels

Influence of β -Blockers on Mortality in Chronic Heart Failure

ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina11This document was approved by the American College of Cardiology Board of Trustees in March 1999, the American Heart Association Science Advisory and Coordinating Committee in March 1999, and the American College of Physicians-American Society of Internal Medicine Board of Regents in February 1999.When citing this document, please use the following citation format: Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, Grunwald MA, Levy D, Lytle BW, O’Rourke RA, Schafer WP, Williams SV. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999;33:2092–197.This document is available on the World Wide Web sites of the American College of Cardiology (www.acc.org) and the American Heart Association (www.americanheart.org). Reprints of this document are available by calling 1-800-253-4636 or writing the American College of Cardiology, Educational Services, at 9111 Old Georgetown Road, Bethesda, MD 20814-1699. Ask for reprint number 71-0166. To obtain a reprint of the Executive Summary and Recommendations published in the June 1, 1999 issue of Circulation, ask for reprint number 71-0167. To purchase bulk reprints (specify version and reprint number): Up to 999 copies call 1-800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies call 214-706-1466, fax 214-691-6342, or e-mail pubauth@heart.org

Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial

Common Genomic Response in Different Mouse Models of β-Adrenergic–Induced Cardiomyopathy

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

L-arginine and nitric oxide-related compounds in plasma: comparison of normal and arginine-free diets in a 24-h crossover study

Endothelial dysfunction in human hand veins is rapidly reversible after smoking cessation

Clinical Effects of β-Adrenergic Blockade in Chronic Heart Failure